Dr. Thorndike joins Nox Health from Pear Therapeutics, where she most recently served as Vice President, Medical Affairs and Discovery, and led the clinical effort for FDA authorization of Somryst, the first FDA-cleared prescription digital therapeutic for chronic insomnia. Previously, Dr. Thorndike was Co-founder and Chief Science Officer of BeHealth Solutions, a start-up focused on disseminating evidence-based digital therapeutics, and has also served as Assistant Professor, Department of Psychiatry and Neurobehavioral Sciences at University of Virginia Health System.

Dr. Ong is a clinical psychologist and a Diplomate in Behavioral Sleep Medicine. He most recently worked at Northwestern University in the Feinberg School of Medicine, where he was an Associate Professor in the Department of Neurology (Sleep Medicine), Medical Social Sciences, and Psychiatry & Behavioral Sciences. Dr. Ong has established himself as a leading authority in behavioral sleep medicine with expertise in mindfulness and sleep health, cognitive behavioral therapy for insomnia (CBTi) and the integration of behavioral sleep medicine across multiple sleep and medical conditions. Over his 17-year academic career, he has received over $10 million in research support and is credited in over 100 publications. He is also the past president of the Society of Behavioral Sleep Medicine and serves on the medical advisory board of several hypersomnia patient organizations.

As the Director of the Clinical Science and Applied Analytics Team, Dr. Ong is responsible for overseeing research operations demonstrating the impact of Nox's medical programs. This includes partnerships with academic researchers on two NIH-funded research studies that are investigating the impact of treating sleep apnea on stroke recovery.

Dr. Ong received his PhD in psychology from Virginia Commonwealth University and completed a fellowship in Behavioral Sleep Medicine at Stanford University.